A Business at a Glance
0 of 1 daily views used (1 remaining). Sign up free for +5 more daily views (6 total), or try AAPL for a full preview.
IMMUCELL CORP /DE/
ICCC
$96M
Mkt Cap
$11.03
+0.91%
IMMUCELL CORP /DE/ (ICCC) has a current P/E ratio of 39.4.
IMMUCELL CORP /DE/ (ICCC) has a 5-year average return on invested capital (ROIC) of -4.5%. This is below average and may indicate limited pricing power.
IMMUCELL CORP /DE/ (ICCC) has a market capitalization of $96M. It is classified as a small-cap stock.
IMMUCELL CORP /DE/ (ICCC) does not currently pay a regular dividend.
IMMUCELL CORP /DE/ (ICCC) operates in the In Vitro & In Vivo Diagnostic Substances industry, within the Healthcare sector.
IMMUCELL CORP /DE/ (ICCC) reported annual revenue of $28 million in its most recent fiscal year, based on SEC EDGAR filings.
IMMUCELL CORP /DE/ (ICCC) has a net profit margin of -3.8%. The company is currently unprofitable.
IMMUCELL CORP /DE/ (ICCC) generated $1 million in free cash flow in its most recent fiscal year. Positive free cash flow supports dividends, buybacks, and debt reduction.
Cautionary Note Regarding Forward-Looking Statements (Safe Harbor Statement): This Annual Report on Form 10-K (Annual Report) contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements can be identified by the fact that they do not relate strictly to historical or current facts and will often include words such as “expects”, “may”, “anticipates”, “aims”, “intends”, “would”, “could”, “should”, “will”, “plans”, “believes”, “estimates”, “targets”, “projects”, “forecasts”, “seeks” and similar words and expressions.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 28M | 28M | 26M | 17M | 19M | 19M |
| Net Income | -1.0M | -1.0M | -2.2M | -5.8M | -2.5M | -78K |
| EPS | $-0.12 | $-0.12 | $-0.26 | $-0.75 | $-0.32 | $-0.01 |
| Free Cash Flow | 1.2M | 1.2M | -108K | -6.6M | -5.5M | -1.7M |
| ROIC | 3.6% | 4.6% | -6.0% | -15.4% | -6.8% | 1.1% |
| Gross Margin | 41.4% | 41.4% | 30.0% | 22.1% | 41.2% | 45.0% |
| Debt/Equity | 0.49 | 0.49 | 0.59 | 1.09 | 0.70 | 0.32 |
| Dividends/Share | $0.00 | $0.00 | - | - | - | - |
| Operating Income | 1.6M | 1.6M | -1.6M | -5.7M | -2.3M | 257K |
| Operating Margin | 6.0% | 6.0% | -6.2% | -32.9% | -12.4% | 1.3% |
| ROE | -3.8% | -3.8% | -8.2% | -20.9% | -7.9% | -0.2% |
| Shares Outstanding | 9M | 9M | 8M | 8M | 8M | 8M |
| Metric | 2014 | 2015 | 2016 | 2017 | 2018 | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||
| Revenue | 7.6M | 10M | 9.5M | 10M | 11M | 14M | 15M | 19M | 19M | 17M | 26M | 28M | 28M |
| Gross Margin | 58.6% | 61.1% | 56.8% | 50.1% | 47.3% | 49.1% | 44.7% | 45.0% | 41.2% | 22.1% | 30.0% | 41.4% | 41.4% |
| R&D | 2.2M | 1.2M | 1.2M | 2.0M | 3.5M | 3.7M | 4.4M | 4.2M | 4.5M | 4.4M | 3.9M | 3.0M | 3.0M |
| SG&A | 1.2M | 1.3M | 1.5M | 1.5M | 1.7M | 1.7M | 1.7M | 1.7M | 2.3M | 2.1M | 2.2M | 3.2M | 3.2M |
| EBIT | -206K | 2.1M | 890K | -243K | -1.4M | -954K | -1.4M | 257K | -2.3M | -5.7M | -1.6M | 1.6M | 1.6M |
| Op. Margin | -2.7% | 20.7% | 9.3% | -2.3% | -13.2% | -7.0% | -9.0% | 1.3% | -12.4% | -32.9% | -6.2% | 6.0% | 6.0% |
| Net Income | -167K | 1.2M | 508K | -168K | -2.3M | -1.3M | -1.0M | -78K | -2.5M | -5.8M | -2.2M | -1.0M | -1.0M |
| Net Margin | -2.2% | 11.9% | 5.3% | -1.6% | -21.1% | -9.4% | -6.7% | -0.4% | -13.4% | -33.1% | -8.1% | -3.8% | -3.8% |
| Non-Recurring | -5K | 4K | -25K | 2K | 700K | 0 | 0 | 0 | 597K | 535K | 15K | -106K | -106K |
| Returns on Capital | |||||||||||||
| ROIC | -1.8% | 19.7% | 7.5% | -0.5% | -7.7% | -3.6% | -2.8% | 1.1% | -6.8% | -15.4% | -6.0% | 4.6% | 3.6% |
| ROE | -1.8% | 12.2% | 3.4% | -0.8% | -10.7% | -4.5% | -3.6% | -0.2% | -7.9% | -20.9% | -8.2% | -3.8% | -3.8% |
| ROA | -1.5% | 9.5% | 2.6% | -0.6% | -7.1% | -3.3% | -2.5% | -0.2% | -5.6% | -13.0% | -4.9% | -2.4% | -2.4% |
| Cash Flow | |||||||||||||
| Op. Cash Flow | 302K | 2.9M | -222K | 1.2M | -373K | 234K | 1.3M | 954K | -1.5M | -4.7M | 358K | 2.5M | 2.5M |
| Free Cash Flow | -1.2M | 181K | -3.8M | -17M | -2.4M | -1.2M | -2.8M | -1.7M | -5.5M | -6.6M | -108K | 1.2M | 1.2M |
| Owner Earnings | -4.2M | -1.9M | -5.7M | -5.0M | -2.2M | -2.3M | -1.3M | -1.6M | -4.3M | -7.8M | -2.7M | -605K | -605K |
| CapEx | 1.5M | 2.7M | 3.6M | 18M | 2.0M | 1.4M | 4.1M | 2.6M | 4.0M | 1.9M | 466K | 1.3M | 1.3M |
| Maint. CapEx | 4.4M | 4.8M | 5.4M | 5.9M | 1.5M | 2.2M | 2.3M | 2.4M | 2.5M | 2.7M | 2.7M | 2.8M | 2.8M |
| Growth CapEx | 0 | 0 | 0 | 12M | 528K | 0 | 1.7M | 167K | 1.5M | 0 | 0 | 0 | 0 |
| D&A | 4.4M | 4.8M | 5.4M | 5.9M | 1.5M | 2.2M | 2.3M | 2.4M | 2.5M | 2.7M | 2.7M | 2.8M | 2.8M |
| CapEx/OCF | N/A | N/A | N/A | N/A | N/A | 595.9% | 309.6% | 273.4% | N/A | N/A | 130.1% | N/A | 50.5% |
| Capital Allocation | |||||||||||||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividend Yield | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | N/A | N/A | N/A | N/A | N/A | N/A | 0.0% | 0.0% |
| Stock-Based Comp | 30K | 23K | 67K | 200K | 344K | 313K | 253K | 144K | 266K | 369K | 326K | 296K | 296K |
| Debt Repayment | 190K | 170K | 136K | 152K | 398K | 861K | 9.6M | 768K | 897K | 1.2M | 1.5M | 2.3M | 2.3M |
| Balance Sheet | |||||||||||||
| Net Debt | -3.2M | -4.0M | -10M | 10M | 14M | 8.2M | 2.8M | -10M | 16M | 26M | 12M | 9.4M | 9.4M |
| Cash & Equiv. | 850K | 1.6M | 5.2M | 3.8M | 2.5M | 6.3M | 6.9M | 10M | 5.8M | 979K | 3.8M | 3.8M | 3.8M |
| Long-Term Debt | 150K | 2.0M | 133K | 9.0M | 8.4M | 7.1M | 8.7M | 8.3M | 9.2M | 11M | 9.0M | 7.5M | 7.5M |
| Debt/Equity | 0.02 | 0.19 | 0.01 | 0.76 | 0.86 | 0.58 | 0.38 | 0.32 | 0.70 | 1.09 | 0.59 | 0.49 | 0.49 |
| Interest Coverage | -3.6 | 25.4 | 5.5 | -1.1 | -3.6 | -2.3 | -2.9 | 0.8 | -6.6 | -12.1 | -2.9 | 3.3 | 3.3 |
| Equity | 9.3M | 11M | 20M | 24M | 22M | 29M | 28M | 33M | 30M | 25M | 28M | 27M | 27M |
| Total Assets | 11M | 15M | 25M | 34M | 33M | 39M | 40M | 44M | 45M | 44M | 45M | 43M | 43M |
| Total Liabilities | 1.8M | 3.9M | 5.0M | 11M | 11M | 9.7M | 12M | 12M | 14M | 19M | 18M | 15M | 15M |
| Intangibles | N/A | N/A | 267K | 248K | 134K | 115K | 96K | 76K | 57K | 38K | 19K | 0 | 0 |
| Retained Earnings | -575K | 639K | 1.1M | 979K | -1.3M | -2.6M | -3.7M | -3.7M | -6.2M | -12M | -14M | -15M | -15M |
| Working Capital | 4.5M | 7.1M | 12M | 5.4M | 3.9M | 11M | 9.9M | 14M | 11M | 7.3M | 11M | 13M | 13M |
| Current Assets | 5.5M | 7.9M | 14M | 7.5M | 6.4M | 13M | 12M | 16M | 14M | 11M | 15M | 17M | 17M |
| Current Liabilities | 1.0M | 793K | 2.1M | 2.1M | 2.6M | 2.5M | 2.2M | 2.5M | 3.1M | 4.2M | 4.4M | 4.0M | 4.0M |
| Per Share Data | |||||||||||||
| EPS | -0.06 | 0.38 | 0.12 | -0.03 | -0.42 | -0.19 | -0.14 | -0.01 | -0.32 | -0.75 | -0.26 | -0.12 | -0.12 |
| Owner EPS | -1.50 | -0.59 | -1.35 | -0.89 | -0.40 | -0.34 | -0.17 | -0.21 | -0.55 | -1.01 | -0.33 | -0.07 | -0.07 |
| Book Value | 3.32 | 3.32 | 4.65 | 4.21 | 3.93 | 4.25 | 3.87 | 4.16 | 3.90 | 3.25 | 3.32 | 3.12 | 3.12 |
| Cash Flow/Share | 0.11 | 0.91 | -0.05 | 0.21 | -0.07 | 0.03 | 0.18 | 0.12 | -0.20 | -0.61 | 0.04 | 0.29 | 0.20 |
| Dividends/Share | 0.00 | 0.00 | 0.00 | 0.00 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 0.00 | 0.00 |
| Shares Out. | 2.8M | 3.2M | 4.2M | 5.6M | 5.5M | 6.8M | 7.3M | 7.8M | 7.8M | 7.7M | 8.3M | 8.7M | 8.7M |
| Valuation | |||||||||||||
| P/E Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | -91.9 |
| P/FCF | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 78.0 |
| EV/EBIT | N/A | N/A | N/A | N/A | N/A | N/A | N/A | 269.6 | N/A | N/A | N/A | N/A | 63.7 |
| Price/Book | N/A | N/A | N/A | N/A | N/A | 1.2 | 1.6 | 2.2 | 1.6 | 1.5 | 1.5 | N/A | 3.5 |
| Price/Sales | N/A | N/A | N/A | N/A | N/A | 3.0 | 2.5 | 3.8 | 3.4 | 2.4 | 1.4 | N/A | 3.5 |
| FCF Yield | N/A | N/A | N/A | N/A | N/A | -3.5% | -5.9% | -2.3% | -11.5% | -17.2% | -0.3% | N/A | 1.3% |
| Market Cap | 0 | 0 | 0 | 0 | 0 | 33M | 47M | 71M | 48M | 38M | 41M | 0 | 96M |
| Avg. Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 6.13 | 5.16 | 9.34 | 8.19 | 5.39 | 4.45 | 0.00 | 11.03 |
| Year-End Price | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 4.90 | 6.38 | 9.10 | 6.16 | 4.95 | 4.98 | 0.00 | 11.03 |
IMMUCELL CORP /DE/ passes 2 of 9 quality checks, indicating weak fundamentals.
The company's 5-year average gross margin is 35.9%.
IMMUCELL CORP /DE/ (ICCC) has a debt-to-equity ratio of 0.49. This indicates a conservatively financed balance sheet.
IMMUCELL CORP /DE/ (ICCC) reported earnings per share (EPS) of $-0.12 in its most recent fiscal year.
IMMUCELL CORP /DE/ (ICCC) has a return on equity (ROE) of -3.8%. A negative ROE may indicate losses or negative equity.
IMMUCELL CORP /DE/ (ICCC) has a 5-year average gross margin of 35.9%. This indicates decent pricing power.
The Ledger Terminal provides 17 years of financial data for IMMUCELL CORP /DE/ (ICCC), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
IMMUCELL CORP /DE/ (ICCC) has a book value per share of $3.12, based on its most recent annual SEC filing.
No recent press releases.